☰

Gerard Sanacora - Publications

Affiliations: 
Yale University, New Haven, CT 
Area:
Psychiatry
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

171/223 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Krystal JH, Kaye AP, Jefferson S, Girgenti MJ, Wilkinson ST, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proceedings of the National Academy of Sciences of the United States of America. 120: e2305772120. PMID 38011560 DOI: 10.1073/pnas.2305772120  0.559
2023 McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, Gorwood P, Ho R, Kasper S, Kennedy SH, Ly-Uson J, Mansur RB, McAllister-Williams RH, Murrough JW, Nemeroff CB, ... ... Sanacora G, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 22: 394-412. PMID 37713549 DOI: 10.1002/wps.21120  0.327
2023 Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, Kakar R, Hassman M, Trivedi RP, Robison R, Gukasyan N, Nayak SM, Hu X, O'Donnell KC, Kelmendi B, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. Jama. PMID 37651119 DOI: 10.1001/jama.2023.14530  0.406
2023 Banasr M, Codeluppi S, Xu M, Bansal Y, Lepack A, Duric V, Chow M, Muir J, Bagot R, Licznerski P, Wilber S, Sanacora G, Sibille E, Duman R, Pittenger C. Prefrontal Cortex Astroglia Modulate Anhedonia-like Behavior. Research Square. PMID 37461693 DOI: 10.21203/rs.3.rs-3093428/v1  0.591
2023 Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, et al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. The New England Journal of Medicine. PMID 37224232 DOI: 10.1056/NEJMoa2302399  0.349
2023 Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, Sanacora G, Wilkinson ST, Popova V, Fu DJ. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 37173512 DOI: 10.1038/s41386-023-01577-5  0.302
2023 Abi-Dargham A, Moeller SJ, Ali F, DeLorenzo C, Domschke K, Horga G, Jutla A, Kotov R, Paulus MP, Rubio JM, Sanacora G, Veenstra-VanderWeele J, Krystal JH. Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 22: 236-262. PMID 37159365 DOI: 10.1002/wps.21078  0.446
2023 Bansal Y, Fee C, Misquitta KA, Codeluppi SA, Sibille E, Berman RM, Coric V, Sanacora G, Banasr M. Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress Models. Complex Psychiatry. 9: 57-69. PMID 37101541 DOI: 10.1159/000529534  0.349
2023 Leal GC, Souza-Marques B, Mello RP, Bandeira ID, Caliman-Fontes AT, Carneiro BA, Faria-Guimarães D, Guerreiro-Costa LNF, Jesus-Nunes AP, Silva SS, Lins-Silva DH, Fontes MA, Alves-Pereira R, Cordeiro V, Rugieri-Pacheco S, ... ... Sanacora G, et al. Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study. Journal of Affective Disorders. 330: 7-15. PMID 36871913 DOI: 10.1016/j.jad.2023.02.151  0.336
2022 Holmes SE, Asch RH, Davis MT, DellaGioia N, Pashankar N, Gallezot JD, Nabulsi N, Matuskey D, Sanacora G, Carson RE, Blumberg HP, Esterlis I. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder. Biological Psychiatry. PMID 36764853 DOI: 10.1016/j.biopsych.2022.10.018  0.368
2022 Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. Jama Psychiatry. PMID 36260324 DOI: 10.1001/jamapsychiatry.2022.3352  0.501
2022 Bloomfield-Clagett B, Ballard ED, Greenstein DK, Wilkinson ST, Grunebaum MF, Murrough JW, Mathew SJ, Phillips JL, Fava M, Sanacora G, Zarate CA. A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Non-Suicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. The International Journal of Neuropsychopharmacology. PMID 35994774 DOI: 10.1093/ijnp/pyac055  0.306
2022 Turkoz I, Lopena O, Salvadore G, Sanacora G, Shelton R, Fu DJ. Treatment response to esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior without evidence of early response: a pooled post hoc analysis of ASPIRE. Cns Spectrums. 1-7. PMID 35904046 DOI: 10.1017/S1092852922000931  0.365
2022 Nikayin S, Rhee TG, Cunningham ME, de Fontnouvelle CA, Ostroff RB, Sanacora G, Wilkinson ST. Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting. Jama Psychiatry. PMID 35544190 DOI: 10.1001/jamapsychiatry.2022.1074  0.32
2022 Averill LA, Jiang L, Purohit P, Coppoli A, Averill CL, Roscoe J, Kelmendi B, De Feyter HM, de Graaf RA, Gueorguieva R, Sanacora G, Krystal JH, Rothman DL, Mason GF, Abdallah CG. Prefrontal Glutamate Neurotransmission in PTSD: A Novel Approach to Estimate Synaptic Strength in Vivo in Humans. Chronic Stress (Thousand Oaks, Calif.). 6: 24705470221092734. PMID 35434443 DOI: 10.1177/24705470221092734  0.347
2022 Holmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K, Davis M, Ropchan J, Emory P, Ye Y, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, ... Sanacora G, et al. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry. PMID 35165397 DOI: 10.1038/s41380-022-01465-2  0.487
2022 Averill LA, Averill CL, Gueorguieva R, Fouda S, Sherif M, Ahn KH, Ranganathan M, D'Souza DC, Southwick SM, Sanacora G, Duman RS, Krystal JH, Abdallah CG. mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. Journal of Affective Disorders. PMID 35101523 DOI: 10.1016/j.jad.2022.01.104  0.49
2021 Nikayin S, Sanacora G. Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk. Cns Drugs. PMID 34491545 DOI: 10.1007/s40263-021-00851-8  0.324
2021 Wilkinson ST, Rhee TG, Joormann J, Webler R, Ortiz Lopez M, Kitay B, Fasula M, Elder C, Fenton L, Sanacora G. Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial. Psychotherapy and Psychosomatics. 1-10. PMID 34186531 DOI: 10.1159/000517074  0.301
2021 Levey DF, Stein MB, Wendt FR, Pathak GA, Zhou H, Aslan M, Quaden R, Harrington KM, Nuñez YZ, Overstreet C, Radhakrishnan K, Sanacora G, McIntosh AM, Shi J, Shringarpure SS, et al. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nature Neuroscience. PMID 34045744 DOI: 10.1038/s41593-021-00860-2  0.311
2021 Banasr M, Sanacora G, Esterlis I. Macro- and Microscale Stress-Associated Alterations in Brain Structure: Translational Link With Depression. Biological Psychiatry. PMID 34001371 DOI: 10.1016/j.biopsych.2021.04.004  0.316
2021 Gruenbaum BF, Sandhu MRS, Bertasi RAO, Bertasi TGO, Schonwald A, Kurup A, Gruenbaum SE, Freedman IG, Funaro MC, Blumenfeld H, Sanacora G. Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality. Epilepsia. PMID 33751566 DOI: 10.1111/epi.16862  0.358
2021 McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. The American Journal of Psychiatry. appiajp202020081251. PMID 33726522 DOI: 10.1176/appi.ajp.2020.20081251  0.404
2020 Pizzagalli DA, Smoski M, Ang YS, Whitton AE, Sanacora G, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu DV, Murrough JW, Yang H, Weiner RD, Calabrese JR, Goodman W, Potter WZ, et al. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32544925 DOI: 10.1038/S41386-020-0738-4  0.315
2020 Pothula S, Kato T, Liu RJ, Wu M, Gerhard D, Shinohara R, Sliby AN, Chowdhury GMI, Behar KL, Sanacora G, Banerjee P, Duman RS. Cell-type specific modulation of NMDA receptors triggers antidepressant actions. Molecular Psychiatry. PMID 32488125 DOI: 10.1038/s41380-020-0796-3  0.354
2020 Averill LA, Abdallah CG, Fenton LR, Fasula MK, Jiang L, Rothman DL, Mason GF, Sanacora G. Early life stress and glutamate neurotransmission in major depressive disorder. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 32418842 DOI: 10.1016/j.euroneuro.2020.03.015  0.391
2020 Fu DJ, Ionescu DF, Li X, Lane R, Lim P, Sanacora G, Hough D, Manji H, Drevets WC, Canuso CM. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). The Journal of Clinical Psychiatry. 81. PMID 32412700 DOI: 10.4088/JCP.19m13191  0.471
2020 Freeman MP, Hock RS, Papakostas GI, Judge H, Cusin C, Mathew SJ, Sanacora G, Iosifescu DV, DeBattista C, Trivedi MH, Fava M. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. Journal of Clinical Psychopharmacology. 40: 287-292. PMID 32332464 DOI: 10.1097/Jcp.0000000000001209  0.46
2020 Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, et al. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). The Journal of Clinical Psychiatry. 81. PMID 32316080 DOI: 10.4088/JCP.19m12891  0.403
2020 Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Calabrese JR, Sanacora G, Hermes G, Keefe RSE, Song A, et al. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nature Medicine. PMID 32231295 DOI: 10.1038/S41591-020-0806-7  0.346
2020 Abdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, Sherif M, Ahn KH, D'Souza DC, Formica R, Southwick SM, Duman RS, Sanacora G, Krystal JH. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32092760 DOI: 10.1038/S41386-020-0644-9  0.598
2020 Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LNF, Marback RF, Caliman-Fontes AT, Marques BLS, Bezerra MLO, Dias-Neto AL, Silva SS, ... ... Sanacora G, et al. Intravenous arketamine for treatment-resistant depression: open-label pilot study. European Archives of Psychiatry and Clinical Neuroscience. PMID 32078034 DOI: 10.1007/S00406-020-01110-5  0.446
2020 Sanacora G. Is This Where We Stand After Decades of Research to Develop More Personalized Treatments for Depression? Jama Psychiatry. PMID 32074267 DOI: 10.1001/jamapsychiatry.2019.4764  0.428
2019 Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, Hough D, Manji H, Drevets WC, Sanacora G, Steffens DC, Adler C, McShane R, Gaillard R, Wilkinson ST, et al. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 31734084 DOI: 10.1016/j.jagp.2019.10.008  0.441
2019 Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. Journal of Affective Disorders. 260: 131-139. PMID 31494365 DOI: 10.1016/J.Jad.2019.09.017  0.443
2019 Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Lower synaptic density is associated with depression severity and network alterations. Nature Communications. 10: 1529. PMID 30948709 DOI: 10.1038/S41467-019-09562-7  0.541
2019 Duman RS, Sanacora G, Krystal JH. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 102: 75-90. PMID 30946828 DOI: 10.1016/J.Neuron.2019.03.013  0.614
2019 Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron. 101: 774-778. PMID 30844397 DOI: 10.1016/J.Neuron.2019.02.005  0.678
2019 Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. Journal of Psychiatric Research. 110: 166-171. PMID 30641350 DOI: 10.1016/J.Jpsychires.2019.01.010  0.384
2019 Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, ... Sanacora G, et al. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry. PMID 30617276 DOI: 10.1038/S41380-018-0311-2  0.374
2019 Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets WC, Sanacora G, Adler C, McShane R, Gaillard R, Singh JB. POST HOC ANALYSES OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION The American Journal of Geriatric Psychiatry. 27: S181-S182. DOI: 10.1016/J.JAGP.2019.01.094  0.424
2019 Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets WC, Sanacora G, Adler C, McShane R, Gaillard R, Singh JB. EFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION The American Journal of Geriatric Psychiatry. 27: S180-S181. DOI: 10.1016/J.Jagp.2019.01.093  0.364
2019 Wajs E, Leah A, Morrison R, Daly E, Lane R, Lim P, Holder R, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, Hough D, et al. Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study European Neuropsychopharmacology. 29. DOI: 10.1016/J.Euroneuro.2018.11.1016  0.399
2019 Holmes S, Scheinost D, Finnema S, Naganawa M, Davis M, DellaGioia N, Nabulsi N, Matuskey D, Angarita G, Pietrzak R, Duman R, Sanacora G, Krystal J, Carson R, Esterlis I. 142. Synaptic Density Alterations are Associated With Depression Severity and Network Alterations Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.156  0.51
2018 Sanacora G, Katz R. Ketamine: A Review for Clinicians. Focus (American Psychiatric Publishing). 16: 243-250. PMID 31975918 DOI: 10.1176/appi.focus.20180012  0.364
2018 Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depression and Anxiety. PMID 30597688 DOI: 10.1002/Da.22875  0.464
2018 Mathew SJ, Wilkinson ST, Altinay M, Asghar-Ali A, Chang LC, Collins KA, Dale RM, Hu B, Krishnan K, Kellner CH, Malone DA, Murrough JW, Ostroff RB, Sanacora G, Shao M, et al. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemporary Clinical Trials. PMID 30572160 DOI: 10.1016/J.Cct.2018.12.009  0.469
2018 Wilkinson ST, Sanacora G. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discovery Today. PMID 30447328 DOI: 10.1016/j.drudis.2018.11.007  0.41
2018 Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, ... Sanacora G, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry. PMID 30283029 DOI: 10.1038/S41380-018-0256-5  0.354
2018 Katz RB, Toprak M, Wilkinson ST, Sanacora G, Ostroff R. Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor. General Hospital Psychiatry. 54: 62-64. PMID 30100209 DOI: 10.1016/j.genhosppsych.2018.05.007  0.457
2018 Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. The Journal of Clinical Psychiatry. 79. PMID 30063304 DOI: 10.4088/JCP.17m11731  0.346
2018 Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GMI, Purohit P, de Graaf RA, Esterlis I, Juchem C, Pittman BP, Krystal JH, Rothman DL, Sanacora G, Mason GF. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 29977074 DOI: 10.1038/S41386-018-0136-3  0.525
2018 Sanacora G. Hopes and Skepticism for Unraveling the Unique Mechanisms of Ketamine's Rapid Onset Antidepressant Actions in Rodent Models. Biological Psychiatry. 84: 7-8. PMID 29929579 DOI: 10.1016/j.biopsych.2018.05.012  0.308
2018 Abdallah CG, Sanacora G, Duman RS, Krystal JH. The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? Pharmacology & Therapeutics. PMID 29803629 DOI: 10.1016/J.Pharmthera.2018.05.010  0.584
2018 Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, Pinter C, Hough D, Sanacora G, Manji H, Drevets WC. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. The American Journal of Psychiatry. appiajp201817060720. PMID 29656663 DOI: 10.1176/Appi.Ajp.2018.17060720  0.393
2018 Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets WC, Sanacora G, Adler C, McShane R, Gaillard R, Singh JB. S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.1005  0.417
2017 van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, Sanacora G. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. Journal of Affective Disorders. 227: 11-16. PMID 29045915 DOI: 10.1016/J.Jad.2017.09.023  0.339
2017 Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, et al. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimulation. PMID 29030111 DOI: 10.1016/J.Brs.2017.09.010  0.424
2017 Abdallah CG, Hannestad J, Mason GF, Holmes SE, DellaGioia N, Sanacora G, Jiang L, Matuskey D, Satodiya R, Gasparini F, Lin X, Javitch J, Planeta B, Nabulsi N, Carson RE, et al. Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 2: 449-456. PMID 28993818 DOI: 10.1016/J.Bpsc.2017.03.019  0.45
2017 Wilkinson ST, Sanacora G, Bloch MH. Hippocampal volume changes following electroconvulsive therapy: a systematic review and meta-analysis. Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 2: 327-335. PMID 28989984 DOI: 10.1016/J.Bpsc.2017.01.011  0.378
2017 Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, Southwick SM, Duman RS. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Current Psychiatry Reports. 19: 74. PMID 28844076 DOI: 10.1007/S11920-017-0829-Z  0.457
2017 Wilkinson ST, Sanacora G. Considerations on the Off-Label Use of Ketamine as a Treatment for Mood Disorders. Jama. PMID 28806440 DOI: 10.1001/jama.2017.10697  0.359
2017 Sanacora G. Ketamine for the Treatment of Depression-Reply. Jama Psychiatry. PMID 28700772 DOI: 10.1001/jamapsychiatry.2017.1776  0.472
2017 Wilkinson ST, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G. A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. The American Journal of Psychiatry. 174: 695-696. PMID 28669202 DOI: 10.1176/appi.ajp.2017.17020239  0.347
2017 Mathew SJ, Gueorguieva R, Brandt C, Fava M, Sanacora G. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28553836 DOI: 10.1038/npp.2017.106  0.486
2017 Wilkinson ST, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, Sanacora G. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. Psychotherapy and Psychosomatics. 86: 162-167. PMID 28490030 DOI: 10.1159/000457960  0.391
2017 Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, Yang J, Pittenger C, Sanacora G, Krystal JH, Parsey RV, Carson RE, DeLorenzo C. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [(11)C]ABP688 and PET imaging study in depression. Molecular Psychiatry. PMID 28397841 DOI: 10.1038/Mp.2017.58  0.696
2017 Medeiros da Frota Ribeiro C, Sanacora G, Ostroff R. Reply to: Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion. Biological Psychiatry. PMID 28262251 DOI: 10.1016/j.biopsych.2017.01.012  0.384
2017 Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. Jama Psychiatry. PMID 28249076 DOI: 10.1001/jamapsychiatry.2017.0080  0.41
2017 Dwyer J, Sanacora G, Bloch M. 1002. Ketamine as a Treatment for Adolescent Major Depressive Disorder Biological Psychiatry. 81: S405. DOI: 10.1016/J.Biopsych.2017.02.729  0.452
2017 Sanacora G, Wilkinson S, Schalkwyk GV. 201. Measuring Dissociative Effects of NMDA Receptor Antagonists in the Treatment of Depression Biological Psychiatry. 81: S83. DOI: 10.1016/j.biopsych.2017.02.214  0.431
2016 Sanacora G, Johnson M, Khan A, Atkinson S, Riesenberg R, Schronen J, Burke MA, Zajecka J, Barra L, Su HL, Posener JA, Bui K, Quirk M, Piser T, Mathew SJ, et al. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 27681442 DOI: 10.1038/Npp.2016.224  0.474
2016 Sanacora G, Heimer H, Hartman D, Mathew SJ, Frye M, Nemeroff C, Beale RR. Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 27640324 DOI: 10.1038/npp.2016.193  0.338
2016 Haroon E, Miller AH, Sanacora G. Inflammation, Glutamate and Glia: A Trio of Trouble in Mood Disorders. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 27629368 DOI: 10.1038/npp.2016.199  0.349
2016 Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AF, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA, Carter CS, Cook EH, Daskalakis ZJ, DiLeone RJ, Duman RS, ... ... Sanacora G, et al. Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biological Psychiatry. 80: 84-6. PMID 27346079 DOI: 10.1016/J.Biopsych.2016.05.004  0.366
2016 Sanacora G. What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive Disorder. Jama Psychiatry. PMID 27303925 DOI: 10.1001/jamapsychiatry.2016.0780  0.435
2016 Wilkinson ST, Sanacora G. KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT? Depression and Anxiety. PMID 27082101 DOI: 10.1002/da.22498  0.315
2016 Chowdhury GM, Zhang J, Thomas M, Banasr M, Ma X, Pittman B, Bristow L, Schaeffer E, Duman RS, Rothman DL, Behar KL, Sanacora G. Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Molecular Psychiatry. PMID 27067013 DOI: 10.1038/mp.2016.34  0.372
2016 Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH. KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS. Depression and Anxiety. PMID 27062302 DOI: 10.1002/Da.22501  0.575
2016 Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. The American Journal of Psychiatry. appiajp201616010037. PMID 27056608 DOI: 10.1176/Appi.Ajp.2016.16010037  0.476
2016 Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nature Medicine. 22: 238-49. PMID 26937618 DOI: 10.1038/Nm.4050  0.595
2016 Krystal JH, Sanacora G, Abdallah C, Duman R. Speaker 4: John Krystal, USA. The International Journal of Neuropsychopharmacology. 19: 19-19. DOI: 10.1093/Ijnp/Pyw042.052  0.363
2015 Niciu MJ, Abdallah CG, Fenton LR, Fasula MK, Black A, Anderson GM, Sanacora G. A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder. Journal of Affective Disorders. 187: 241-4. PMID 26363143 DOI: 10.1016/J.Jad.2015.08.026  0.41
2015 Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. The Journal of Clinical Psychiatry. 76: 1075-84. PMID 26214725 DOI: 10.4088/Jcp.14M09123  0.619
2015 da Frota Ribeiro CM, Sanacora G, Hoffman R, Ostroff R. The Use of Ketamine for the Treatment of Depression in the Context of Psychotic Symptoms: To the Editor. Biological Psychiatry. PMID 26212896 DOI: 10.1016/J.Biopsych.2015.05.016  0.443
2015 McCullumsmith RE, Sanacora G. Regulation of extrasynaptic glutamate levels as a pathophysiological mechanism in disorders of motivation and addiction. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 254-5. PMID 25482181 DOI: 10.1038/Npp.2014.218  0.351
2015 Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annual Review of Medicine. 66: 509-23. PMID 25341010 DOI: 10.1146/Annurev-Med-053013-062946  0.62
2015 Sanacora G, Schatzberg AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 259-67. PMID 25257213 DOI: 10.1038/npp.2014.261  0.427
2015 DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, Yang J, Wen R, Mann JJ, Krystal JH, Parsey RV, Carson RE, Esterlis I. In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biological Psychiatry. 77: 266-75. PMID 25156701 DOI: 10.1016/J.Biopsych.2014.06.024  0.367
2015 Da Frota Ribeiro CM, Sanacora G, Hoffman R, Ostroff R. The Use of Ketamine for the Treatment of Depression in the Context of Psychotic Symptoms Biological Psychiatry. DOI: 10.1016/j.biopsych.2015.05.016  0.336
2014 Abdallah CG, Niciu MJ, Fenton LR, Fasula MK, Jiang L, Black A, Rothman DL, Mason GF, Sanacora G. Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder. Psychotherapy and Psychosomatics. 83: 298-307. PMID 25116726 DOI: 10.1159/000361078  0.445
2014 Abdallah CG, Jiang L, De Feyter HM, Fasula M, Krystal JH, Rothman DL, Mason GF, Sanacora G. Glutamate metabolism in major depressive disorder. The American Journal of Psychiatry. 171: 1320-7. PMID 25073688 DOI: 10.1176/Appi.Ajp.2014.14010067  0.571
2014 Niciu MJ, Henter ID, Sanacora G, Zarate CA. Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity? The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 15: 2-16. PMID 24024876 DOI: 10.3109/15622975.2013.829585  0.443
2014 Singh J, Fedgchin M, Daly E, Boer PD, Cooper K, Lim P, Pinter C, Murrough J, Sanacora G, Shelton R, Kurian B, Winokur A, Fava M, Manji H, Drevets W, et al. P.2.b.017 Onset of efficacy of ketamine in treatment-resistant depression: a double-blind, randomised, placebo-controlled, dose frequency study European Neuropsychopharmacology. 24. DOI: 10.1016/S0924-977X(14)70618-2  0.401
2013 Voleti B, Navarria A, Liu RJ, Banasr M, Li N, Terwilliger R, Sanacora G, Eid T, Aghajanian G, Duman RS. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biological Psychiatry. 74: 742-9. PMID 23751205 DOI: 10.1016/J.Biopsych.2013.04.025  0.372
2013 Sanacora G, Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biological Psychiatry. 73: 1172-9. PMID 23726152 DOI: 10.1016/j.biopsych.2013.03.032  0.459
2013 Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biological Psychiatry. 73: 1133-41. PMID 23726151 DOI: 10.1016/J.Biopsych.2013.03.026  0.537
2013 Cardoos A, Inamori A, Sanacora G, Fava M, Mischoulon D. Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report. Psychosomatics. 54: 488-92. PMID 23473447 DOI: 10.1016/j.psym.2013.02.002  0.473
2013 Sanacora G, Duman RS. The revolution in rapid-acting antidepressants Biological Psychiatry. 73: 1123-1124. DOI: 10.1016/j.biopsych.2013.04.020  0.403
2012 Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. The Journal of Ect. 28: 157-61. PMID 22847373 DOI: 10.1097/YCT.0b013e31824f8296  0.499
2012 Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biological Psychiatry. 72: 964-70. PMID 22784486 DOI: 10.1016/J.Biopsych.2012.05.028  0.704
2012 Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biological Psychiatry. 72: e27-8. PMID 22771240 DOI: 10.1016/J.Biopsych.2012.05.031  0.415
2012 McCarthy DJ, Alexander R, Smith MA, Pathak S, Kanes S, Lee CM, Sanacora G. Glutamate-based depression GBD. Medical Hypotheses. 78: 675-81. PMID 22391030 DOI: 10.1016/j.mehy.2012.02.009  0.497
2012 Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. ¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biological Psychiatry. 71: 1022-5. PMID 22169441 DOI: 10.1016/j.biopsych.2011.11.006  0.322
2012 Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nature Reviews. Neuroscience. 13: 22-37. PMID 22127301 DOI: 10.1038/Nrn3138  0.313
2012 Siegel S, Sanacora G. The roles of glutamate receptors across major neurological and psychiatric disorders. Pharmacology, Biochemistry, and Behavior. 100: 653-5. PMID 22108650 DOI: 10.1016/j.pbb.2011.11.002  0.351
2012 Niciu MJ, Kelmendi B, Sanacora G. Overview of glutamatergic neurotransmission in the nervous system. Pharmacology, Biochemistry, and Behavior. 100: 656-64. PMID 21889952 DOI: 10.1016/J.Pbb.2011.08.008  0.334
2012 Gomez R, Behar KL, Watzl J, Weinzimer SA, Gulanski B, Sanacora G, Koretski J, Guidone E, Jiang L, Petrakis IL, Pittman B, Krystal JH, Mason GF. Intravenous ethanol infusion decreases human cortical γ-aminobutyric acid and N-acetylaspartate as measured with proton magnetic resonance spectroscopy at 4 tesla. Biological Psychiatry. 71: 239-46. PMID 21855054 DOI: 10.1016/J.Biopsych.2011.06.026  0.442
2012 Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 62: 63-77. PMID 21827775 DOI: 10.1016/J.Neuropharm.2011.07.036  0.515
2012 Gourley SL, Espitia JW, Sanacora G, Taylor JR. Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacology. 219: 805-14. PMID 21779782 DOI: 10.1007/s00213-011-2403-4  0.38
2011 Kelmendi B, Holsbach-Beltrame M, McIntosh AM, Hilt L, George ED, Kitchen RR, Carlyle BC, Pittenger C, Coric V, Nolen-Hoeksema S, Sanacora G, Simen AA. Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder. Neuroscience Letters. 496: 195-9. PMID 21529705 DOI: 10.1016/J.Neulet.2011.04.026  0.574
2011 Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Research. 191: 122-7. PMID 21232924 DOI: 10.1016/J.Pscychresns.2010.10.009  0.575
2011 Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, Lorberg B, Pittman B, Bhagwagar Z. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. The Journal of Clinical Psychiatry. 72: 744-50. PMID 21034692 DOI: 10.4088/JCP.09m05659gre  0.484
2011 Larkin G, Beautrais A, Turelli R, Sanacora G, Powsner S, Lippmann M, Krystal J. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department European Psychiatry. 26: 1607-1607. DOI: 10.1016/S0924-9338(11)73311-9  0.489
2010 Husky MM, Gindre C, Mazure CM, Brebant C, Nolen-Hoeksema S, Sanacora G, Swendsen J. Computerized ambulatory monitoring in mood disorders: feasibility, compliance, and reactivity. Psychiatry Research. 178: 440-2. PMID 20488558 DOI: 10.1016/J.Psychres.2010.04.045  0.421
2010 Sanacora G. Cortical inhibition, gamma-aminobutyric acid, and major depression: there is plenty of smoke but is there fire? Biological Psychiatry. 67: 397-8. PMID 20159143 DOI: 10.1016/j.biopsych.2010.01.003  0.38
2010 Maciag D, Hughes J, O'Dwyer G, Pride Y, Stockmeier CA, Sanacora G, Rajkowska G. Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies. Biological Psychiatry. 67: 465-70. PMID 20004363 DOI: 10.1016/J.Biopsych.2009.10.027  0.459
2010 Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Molecular Psychiatry. 15: 501-11. PMID 18825147 DOI: 10.1038/mp.2008.106  0.426
2010 Sanacora G, Banasr M, Chowdhury G, Lepak A, Behar K. S.28.05 Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioural deficits by the glutamate-modulating drug riluzole European Neuropsychopharmacology. 20. DOI: 10.1016/S0924-977X(10)70241-8  0.385
2010 Larkin G, Beautrais A, Powsner S, Sanacora G, Krystal J, Turelli R, Lippmann M. 157: A Prospective Open Label Trial of Low Dose Ketamine for Acute Suicidal States In the Emergency Department Annals of Emergency Medicine. 56: S53. DOI: 10.1016/J.ANNEMERGMED.2010.06.204  0.327
2010 Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target of the pharmacotherapy of anxiety disorders, mood disorders and schizophrenia | Neuroplastyczność jako cel dla farmakoterapii zaburzeń lȩkowych, zaburzeń nastroju i schizofrenii Wiadomosci Psychiatryczne. 13: 163-173.  0.411
2009 Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today. 14: 690-7. PMID 19460458 DOI: 10.1016/J.Drudis.2009.05.002  0.508
2009 Valentine GW, Sanacora G. Targeting glial physiology and glutamate cycling in the treatment of depression. Biochemical Pharmacology. 78: 431-9. PMID 19376090 DOI: 10.1016/j.bcp.2009.04.008  0.426
2009 Sanacora G. Reviewing medications for bipolar disorder: understanding the mechanisms of action. The Journal of Clinical Psychiatry. 70: e02. PMID 19222977 DOI: 10.4088/Jcp.7128Br6C.E02  0.361
2009 Saricicek A, Maloney K, Lorberg B, Muralidharan A, Ruf B, Blumberg H, Hu J, Pittman B, Sanacora G, Bhagwagar Z. P.2.e.029 Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo controlled trial European Neuropsychopharmacology. 19: S465. DOI: 10.1016/S0924-977X(09)70728-X  0.388
2008 Sanacora G. New understanding of mechanisms of action of bipolar medications. The Journal of Clinical Psychiatry. 69: 22-7. PMID 19265637  0.366
2008 Sen S, Sanacora G. Major depression: emerging therapeutics. The Mount Sinai Journal of Medicine, New York. 75: 204-25. PMID 18704976 DOI: 10.1002/Msj.20043  0.469
2008 Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the treatment of mood and anxiety disorders. Cns Drugs. 22: 761-86. PMID 18698875 DOI: 10.2165/00023210-200822090-00004  0.703
2008 Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biological Psychiatry. 64: 527-32. PMID 18571629 DOI: 10.1016/J.Biopsych.2008.05.005  0.463
2008 Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews. Drug Discovery. 7: 426-37. PMID 18425072 DOI: 10.1038/Nrd2462  0.51
2008 Krystal JH, Carter CS, Geschwind D, Manji HK, March JS, Nestler EJ, Zubieta JK, Charney DS, Goldman D, Gur RE, Lieberman JA, Roy-Byrne P, Rubinow DR, Anderson SA, Barondes S, ... ... Sanacora G, et al. It is time to take a stand for medical research and against terrorism targeting medical scientists. Biological Psychiatry. 63: 725-7. PMID 18371494 DOI: 10.1016/J.Biopsych.2008.03.005  0.491
2007 Sanacora G, Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. Cns & Neurological Disorders Drug Targets. 6: 127-40. PMID 17430150 DOI: 10.2174/187152707780363294  0.48
2007 Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. Cns & Neurological Disorders Drug Targets. 6: 101-15. PMID 17430148 DOI: 10.2174/187152707780363267  0.709
2007 Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biological Psychiatry. 61: 822-5. PMID 17141740 DOI: 10.1016/J.Biopsych.2006.08.037  0.625
2007 Mineur YS, Picciotto MR, Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biological Psychiatry. 61: 250-2. PMID 16860779 DOI: 10.1016/j.biopsych.2006.04.037  0.689
2006 Fenton L, Fasula M, Ostroff R, Sanacora G. Can cognitive behavioral therapy reduce relapse rates of depression after ECT? a preliminary study. The Journal of Ect. 22: 196-8. PMID 16957536 DOI: 10.1097/01.yct.0000235201.42287.b4  0.439
2006 Pittenger C, Naungayan C, Kendell SF, Coric V, Malison R, Krystal JH, Sanacora GS. Visual hallucinations from the addition of riluzole to memantine and bupropion. Journal of Clinical Psychopharmacology. 26: 218-20. PMID 16633160 DOI: 10.1097/01.Jcp.0000203228.64117.9F  0.526
2006 Geracioti TD, Carpenter LL, Owens MJ, Baker DG, Ekhator NN, Horn PS, Strawn JR, Sanacora G, Kinkead B, Price LH, Nemeroff CB. Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. The American Journal of Psychiatry. 163: 637-43. PMID 16585438 DOI: 10.1176/Ajp.2006.163.4.637  0.37
2006 Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology. 184: 254-6. PMID 16374600 DOI: 10.1007/S00213-005-0246-6  0.678
2006 Staley JK, Sanacora G, Tamagnan G, Maciejewski PK, Malison RT, Berman RM, Vythilingam M, Kugaya A, Baldwin RM, Seibyl JP, Charney D, Innis RB. Sex differences in diencephalon serotonin transporter availability in major depression. Biological Psychiatry. 59: 40-7. PMID 16139815 DOI: 10.1016/J.Biopsych.2005.06.012  0.556
2006 Sanacora G, Fenton LR, Fasula MK, Rothman DL, Levin Y, Krystal JH, Mason GF. Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biological Psychiatry. 59: 284-6. PMID 16139814 DOI: 10.1016/J.Biopsych.2005.07.015  0.57
2005 Kugaya A, Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. Cns Spectrums. 10: 808-19. PMID 16400244 DOI: 10.1017/S1092852900010403  0.48
2005 Ostroff R, Gonzales M, Sanacora G. Antidepressant effect of ketamine during ECT. The American Journal of Psychiatry. 162: 1385-6. PMID 15994728 DOI: 10.1176/appi.ajp.162.7.1385  0.411
2005 Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biological Psychiatry. 58: 424-8. PMID 15993857 DOI: 10.1016/J.Biopsych.2005.04.043  0.688
2005 Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opinion On Therapeutic Targets. 9: 153-68. PMID 15757488 DOI: 10.1517/14728222.9.1.153  0.503
2005 Epperson CN, O'Malley S, Czarkowski KA, Gueorguieva R, Jatlow P, Sanacora G, Rothman DL, Krystal JH, Mason GF. Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biological Psychiatry. 57: 44-8. PMID 15607299 DOI: 10.1016/J.Biopsych.2004.09.021  0.446
2004 Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH. Riluzole augmentation for treatment-resistant depression. The American Journal of Psychiatry. 161: 2132. PMID 15514421 DOI: 10.1176/Appi.Ajp.161.11.2132  0.56
2004 Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, Anand A, Van Dyck CH, Baldwin RM, Seibyl JP, Charney D, Innis RB. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biological Psychiatry. 56: 497-502. PMID 15450785 DOI: 10.1016/J.Biopsych.2004.07.001  0.541
2004 Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Archives of General Psychiatry. 61: 705-13. PMID 15237082 DOI: 10.1001/Archpsyc.61.7.705  0.551
2004 Sanacora G, Berman RM, Cappiello A, Oren DA, Kugaya A, Liu N, Gueorguieva R, Fasula D, Charney DS. Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 29: 1166-71. PMID 15010697 DOI: 10.1038/Sj.Npp.1300418  0.487
2004 Perry EB, Berman RM, Sanacora G, Anand A, Lynch-Colonese K, Charney DS. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. The Journal of Clinical Psychiatry. 65: 238-43. PMID 15003079 DOI: 10.4088/Jcp.V65N0215  0.577
2004 Lappalainen J, Sanacora G, Kranzler HR, Malison R, Hibbard ES, Price LH, Krystal J, Gelernter J. Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 124: 81-6. PMID 14681921 DOI: 10.1002/Ajmg.B.20055  0.519
2003 Sanacora G, Rothman DL, Mason G, Krystal JH. Clinical studies implementing glutamate neurotransmission in mood disorders. Annals of the New York Academy of Sciences. 1003: 292-308. PMID 14684453 DOI: 10.1196/Annals.1300.018  0.507
2003 Kugaya A, Sanacora G, Verhoeff NP, Fujita M, Mason GF, Seneca NM, Bozkurt A, Khan SA, Anand A, Degen K, Charney DS, Zoghbi SS, Baldwin RM, Seibyl JP, Innis RB. Cerebral benzodiazepine receptors in depressed patients measured with [123I]iomazenil SPECT. Biological Psychiatry. 54: 792-9. PMID 14550678 DOI: 10.1016/S0006-3223(02)01788-2  0.539
2003 Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, Berman RM, Krystal JH. Increased cortical GABA concentrations in depressed patients receiving ECT. The American Journal of Psychiatry. 160: 577-9. PMID 12611844 DOI: 10.1176/Appi.Ajp.160.3.577  0.555
2002 Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry. 7: S71-80. PMID 11986998 DOI: 10.1038/Sj.Mp.4001021  0.644
2002 Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. The American Journal of Psychiatry. 159: 663-5. PMID 11925309 DOI: 10.1176/Appi.Ajp.159.4.663  0.557
2002 Berman RM, Sanacora G, Anand A, Roach LM, Fasula MK, Finkelstein CO, Wachen RM, Oren DA, Heninger GR, Charney DS. Monoamine depletion in unmedicated depressed subjects. Biological Psychiatry. 51: 469-73. PMID 11922881 DOI: 10.1016/S0006-3223(01)01285-9  0.58
2001 Krystal JH, D'Souza DC, Sanacora G, Goddard AW, Charney DS. Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. The Medical Clinics of North America. 85: 559-77. PMID 11349473 DOI: 10.1016/S0025-7125(05)70329-1  0.623
2001 Chen AC, Shin KH, Duman RS, Sanacora G. ECS-Induced mossy fiber sprouting and BDNF expression are attenuated by ketamine pretreatment. The Journal of Ect. 17: 27-32. PMID 11281511 DOI: 10.1097/00124509-200103000-00006  0.336
2000 Sanacora G, Mason GF, Krystal JH. Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Critical Reviews in Neurobiology. 14: 23-45. PMID 11253954 DOI: 10.1615/Critrevneurobiol.V14.I1.20  0.598
2000 Berman RM, Narasimhan M, Sanacora G, Miano AP, Hoffman RE, Hu XS, Charney DS, Boutros NN. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biological Psychiatry. 47: 332-7. PMID 10686268 DOI: 10.1016/S0006-3223(99)00243-7  0.576
2000 Sanacora G, Mason G, Rothman D, Epperson C, Goddard A, Krystal J. 305. Reduced cortical GABA in depression is not due to decreased gray matter Biological Psychiatry. 47: S92. DOI: 10.1016/S0006-3223(00)00569-2  0.552
2000 Mason G, Sanacora G, Anand A, Epperson C, Goddard A, Rothman D, Charney D, Krystal J. 304. Cortical GABA reduced in unipolar but not bipolar depression Biological Psychiatry. 47: S92. DOI: 10.1016/S0006-3223(00)00568-0  0.571
2000 Berman R, Sanacora G, Narasimhan M, Oren D, Cappiello A, Charney D. 268. Simultaneous catecholamine and indoleamine depletion in unmedicated depressed subjects Biological Psychiatry. 47: S81. DOI: 10.1016/S0006-3223(00)00532-1  0.491
1999 Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, Berman RM, Charney DS, Krystal JH. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Archives of General Psychiatry. 56: 1043-7. PMID 10565505 DOI: 10.1001/Archpsyc.56.11.1043  0.622
1999 Sanacora G, Rothman D, Krystal JH. Applications of magnetic resonance spectroscopy to psychiatry Neuroscientist. 5: 192-196. DOI: 10.1177/107385849900500316  0.415
1999 Sanacora G, Mason GF, Rothman DL, Berman RM, Charney DS, Ciarcia JJ, Krystal JH. 1. ECT Effects on Cortical GABA Levels as Determined by 1H-MRS The Journal of Ect. 15: 102. DOI: 10.1097/00124509-199903000-00009  0.534
1998 Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biological Psychiatry. 44: 1090-8. PMID 9836013 DOI: 10.1016/S0006-3223(98)00272-8  0.536
1998 Berman R, Boutros N, Narasimhan M, Sanacora G, Charney D. 322. Transcranial magnetic stimulation in treatment-refractory depression Biological Psychiatry. 43: S97. DOI: 10.1016/S0006-3223(98)90770-3  0.47
1998 Sanacora G, Goddard A, Gil R, D'Souza D, Abi-Saab W, Petroff O, Mattson R, Mason G, Behar K, Ciarcia J, Berman R, Charney D, Rothman D, Krystal J. 24. Quantification of cortical GABA levels in neuropsychiatric patients Biological Psychiatry. 43: S8. DOI: 10.1016/S0006-3223(98)90472-3  0.358
Low-probability matches (unlikely to be authored by this person)
2019 Sanacora G. Caution Against Overinterpreting Opiate Receptor Stimulation as Mediating Antidepressant Effects of Ketamine. The American Journal of Psychiatry. 176: 249. PMID 30818992 DOI: 10.1176/appi.ajp.2018.18091061  0.298
2002 Cubells JF, Price LH, Meyers BS, Anderson GM, Zabetian CP, Alexopoulos GS, Nelson JC, Sanacora G, Kirwin P, Carpenter L, Malison RT, Gelernter J. Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression. Biological Psychiatry. 51: 358-64. PMID 11904129 DOI: 10.1016/S0006-3223(01)01349-X  0.298
2022 Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. Focus (American Psychiatric Publishing). 20: 241-251. PMID 37153136 DOI: 10.1176/appi.focus.22020004  0.293
2021 Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. The American Journal of Psychiatry. appiajp202020010018. PMID 33653121 DOI: 10.1176/appi.ajp.2020.20010018  0.293
2017 Sanacora G, Chowdhury G, Rothman D, Behar K. 662. Ketamine and Rapastinel Effects on Glutamate Cycling Biological Psychiatry. 81: S268. DOI: 10.1016/j.biopsych.2017.02.1071  0.292
2019 Webler R, Wilkinson S, Kirwin D, Bloch M, Kitay B, Sanacora G. S128. Expectancy and Ketamine’s Rapid Antidepressant Effect: A Meta-Analysis Biological Psychiatry. 85: S346. DOI: 10.1016/J.Biopsych.2019.03.879  0.29
2022 Bandeira ID, Lins-Silva DH, Cavenaghi VB, Dorea-Bandeira I, Faria-Guimarães D, Barouh JL, Jesus-Nunes AP, Beanes G, Souza LS, Leal GC, Sanacora G, Miguel EC, Sampaio AS, Quarantini LC. Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harvard Review of Psychiatry. 30: 135-145. PMID 35267254 DOI: 10.1097/HRP.0000000000000330  0.283
2008 Chowdhury GM, Banasr M, de Graaf RA, Rothman DL, Behar KL, Sanacora G. Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 28: 1892-7. PMID 18628780 DOI: 10.1038/jcbfm.2008.78  0.274
2009 Sanacora G. Do glutamatergic agents represent a new class of antidepressant drugs? Part 2. The Journal of Clinical Psychiatry. 70: 1604-5. PMID 20031105 DOI: 10.4088/JCP.09ac05757blu  0.274
2009 Sanacora G. Do glutamatergic agents represent a new class of antidepressant drugs? Part 1. The Journal of Clinical Psychiatry. 70: 1473-5. PMID 19906350 DOI: 10.4088/JCP.09ac05680blu  0.274
2021 Ochs-Ross R, Wajs E, Daly EJ, Zhang Y, Lane R, Lim P, Drevets WC, Steffens DC, Sanacora G, Jamieson C, Hough D, Manji H, Singh JB. Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 34750057 DOI: 10.1016/j.jagp.2021.09.014  0.271
2006 Gueorguieva RV, Sanacora G. Joint analysis of repeatedly observed continuous and ordinal measures of disease severity. Statistics in Medicine. 25: 1307-22. PMID 16217846 DOI: 10.1002/sim.2270  0.267
2014 Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Molecular Psychiatry. 19: 978-85. PMID 24126931 DOI: 10.1038/mp.2013.130  0.267
2017 Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Sanacora G. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. The American Journal of Psychiatry. appiajp201717040472. PMID 28969441 DOI: 10.1176/Appi.Ajp.2017.17040472  0.265
2017 Banasr M, Lepack A, Fee C, Duric V, Maldonado-Aviles J, DiLeone R, Sibille E, Duman RS, Sanacora G. Characterization of GABAergic marker expression in the chronic unpredictable stress model of depression. Chronic Stress (Thousand Oaks, Calif.). 1. PMID 28835932  0.263
2023 Kitay BM, Murphy E, Macaluso M, Corlett PR, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee TG, Sanacora G, Shelton RC, Thase ME, Wilkinson ST. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol. Psychiatry Research. 330: 115585. PMID 37935086 DOI: 10.1016/j.psychres.2023.115585  0.263
2019 Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, Pinter C, Hough D, Sanacora G, Manji H, Drevets WC. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Focus (American Psychiatric Publishing). 17: 55-65. PMID 32015715 DOI: 10.1176/appi.focus.17105  0.258
2018 Wilkinson S, Webler R, Katz R, Toprak M, Ostroff R, Sanacora G. S106. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.997  0.255
2006 Kelmendi B, Saricicek A, Sanacora G. The role of the glutamatergic system in the pathophysiology and treatment of mood disorders Primary Psychiatry. 13: 80-86.  0.254
2022 Feeney A, Hoeppner BB, Freeman MP, Flynn M, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, DeBattista C, Ionescu DF, Cusin C, Papakostas GI, Jha MK, Fava M. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. The Journal of Clinical Psychiatry. 84. PMID 36383742 DOI: 10.4088/JCP.22m14491  0.253
2015 Niciu MJ, Abdallah CG, Fenton LR, Fasula MK, Black A, Anderson GM, Sanacora G. A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder Journal of Affective Disorders. 187: 241-244. DOI: 10.1016/j.jad.2015.08.026  0.252
2012 Morgan PT, Pace-Schott EF, Mason GF, Forselius E, Fasula M, Valentine GW, Sanacora G. Cortical GABA levels in primary insomnia. Sleep. 35: 807-14. PMID 22654200 DOI: 10.5665/sleep.1880  0.252
2018 Holmes S, Finnema S, Davis M, DellaGioia N, Naganawa M, Nabulsi N, Matuskey D, Pietrzak R, Duman R, Sanacora G, Carson R, Esterlis I. F149. Preliminary Evidence for Altered Synaptic Density and a Possible Role for Accelerated Ageing in Individuals With MDD as Measured With [11C]UCB-J PET Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.763  0.24
2019 Krystal A, Pizzagalli D, Smoski M, Mathew S, Nurnberger J, Lisanby S, Iosifescu D, Murrough J, Weiner R, Calabrese J, Sanacora G, Keefe R, Song A, Goodman W, Szabo S, et al. 116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients Biological Psychiatry. 85: S48-S49. DOI: 10.1016/J.Biopsych.2019.03.130  0.239
2018 Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, Calabrese J, Goddard A, Goodman W, Lisanby SH, Smoski M, Weiner R, Iosifescu D, Nurnberger J, Szabo S, et al. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nature Reviews. Drug Discovery. 18: 82-84. PMID 30591715 DOI: 10.1038/Nrd.2018.222  0.237
2005 Sabharwal P, Simen BB, Sanacora G. Depressed diabetics: A neuroimmunologic syndrome? Primary Psychiatry. 12: 42-46.  0.228
2018 Wilkinson ST, Sanacora G. Authorship Credit for Large Clinical Trials. Jama. 319: 722-723. PMID 29466586 DOI: 10.1001/jama.2017.20939  0.225
2021 Feeney A, Hock RS, Freeman MP, Flynn M, Hoeppner B, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Fava M, Papakostas GI. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 49: 122-132. PMID 34090255 DOI: 10.1016/j.euroneuro.2021.04.024  0.223
2016 Wilkinson ST, Ostroff RB, Sanacora G. Computer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy. The Journal of Ect. PMID 27564424 DOI: 10.1097/YCT.0000000000000348  0.222
2015 Sanacora G, Schatzberg AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 1307. PMID 25767082 DOI: 10.1038/npp.2014.338  0.215
1992 Schwartz MW, Sipols AJ, Marks JL, Sanacora G, White JD, Scheurink A, Kahn SE, Baskin DG, Woods SC, Figlewicz DP. Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology. 130: 3608-16. PMID 1597158 DOI: 10.1210/Endo.130.6.1597158  0.214
2023 Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. Drug Discovery Today. 28: 103818. PMID 37925136 DOI: 10.1016/j.drudis.2023.103818  0.212
1999 Sanacora G, -H. Chen AC, Shin K, Duman RS. 8. Ketamine Effects on ECS Induced BDNF Expression and Mossy Fiber Sprouting The Journal of Ect. 15: 109. DOI: 10.1097/00124509-199903000-00028  0.211
2017 Klingensmith KE, Sanacora G, Ostroff R. Co-occurring Catatonia and Posterior Reversible Encephalopathy Syndrome Responsive to Electroconvulsive Therapy. The Journal of Ect. PMID 28383349 DOI: 10.1097/YCT.0000000000000407  0.207
1992 Camp P, Sahu A, Sanacora G, Ponsalle P, White JD. Gene expression of peptidergic signals: Effects of steroids Neuroprotocols. 1: 67-76. DOI: 10.1016/1058-6741(92)90022-P  0.207
2015 Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A pilot randomized placebo-controlled trial Journal of Clinical Psychiatry. 76: 1075-1084. DOI: 10.4088/JCP.14m09123  0.206
2021 Sanacora G, Yan Z, Popoli M. The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders. Nature Reviews. Neuroscience. PMID 34893785 DOI: 10.1038/s41583-021-00540-x  0.204
2008 Nierenberg AA, Ketter TA, Perlis RH, Sanacora G, Thase ME. Easing the burden of bipolar disorder: From urgent situations to remission Primary Care Companion to the Journal of Clinical Psychiatry. 10: 391-402.  0.201
1990 Sanacora G, Kershaw M, Finkelstein JA, White JD. Increased hypothalamic content of preproneuropeptide Y messenger ribonucleic acid in genetically obese Zucker rats and its regulation by food deprivation. Endocrinology. 127: 730-7. PMID 2373052 DOI: 10.1210/endo-127-2-730  0.2
2021 Pizzagalli DA, Smoski M, Ang YS, Whitton AE, Sanacora G, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu DV, Murrough JW, Yang H, Weiner RD, Calabrese JR, Goodman W, Potter WZ, et al. Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 34389811 DOI: 10.1038/s41386-021-01145-9  0.198
1992 Sanacora G, Finkelstein JA, Whitet JD. Developmental aspect of differences in hypothalamic preproneuropeptide y messenger ribonucleic Acid content in lean and genetically obese zucker rats. Journal of Neuroendocrinology. 4: 353-7. PMID 21554617 DOI: 10.1111/j.1365-2826.1992.tb00179.x  0.195
1990 White JD, Kershaw M, Sanacora G, Olchovsky D, Finkelstein JA, Berelowitz M. Hypothalamic neuropeptide Y expression in normal and aberrant metabolic homeostasis Annals of the New York Academy of Sciences. 611: 480-482. DOI: 10.1111/J.1749-6632.1990.Tb48992.X  0.189
1996 Chang R, Sanacora G, Sanchez R. The need for outcome studies. Journal of the American Academy of Child and Adolescent Psychiatry. 35: 557. PMID 8935198 DOI: 10.1097/00004583-199605000-00005  0.184
2020 Miller CO, Gantert LT, Previs SF, Chen Y, Anderson KD, Thomas JM, Sanacora G, Uslaner JM, Rothman DL, Mason GF. A Novel Biomarker of Neuronal Glutamate Metabolism in Nonhuman Primates Using Localized H-Magnetic Resonance Spectroscopy: Development and Effects of BNC375, an α7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator. Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. PMID 33309567 DOI: 10.1016/j.bpsc.2020.09.014  0.168
2014 Kiselycznyk C, Sanacora G. Using our understanding of stress-related effects on glutamate neurotransmission to guide the development of novel treatment strategies Synaptic Stress and Pathogenesis of Neuropsychiatric Disorders. 313-342. DOI: 10.1007/978-1-4939-1056-4_17  0.165
2014 Popoli M, Diamond D, Sanacora G. Synaptic stress and pathogenesis of neuropsychiatric disorders Synaptic Stress and Pathogenesis of Neuropsychiatric Disorders. 1-355. DOI: 10.1007/978-1-4939-1056-4  0.152
2012 Sanacora G. Ketamine-induced optimism: New hope for the development of rapid-acting antidepressants Psychiatric Times. 29: 1+3-7.  0.135
2024 Wilkinson ST, Palamar JJ, Sanacora G. The Rapidly Shifting Ketamine Landscape in the US. Jama Psychiatry. PMID 38170542 DOI: 10.1001/jamapsychiatry.2023.4945  0.12
2023 Darrow SM, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Sanacora G, Keefe RSE, Song A, Goodman W, Whitton AE, et al. Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study. Journal of Affective Disorders. PMID 37467805 DOI: 10.1016/j.jad.2023.07.081  0.115
2022 Greene AS, Shen X, Noble S, Horien C, Hahn CA, Arora J, Tokoglu F, Spann MN, Carrión CI, Barron DS, Sanacora G, Srihari VH, Woods SW, Scheinost D, Constable RT. Brain-phenotype models fail for individuals who defy sample stereotypes. Nature. 609: 109-118. PMID 36002572 DOI: 10.1038/s41586-022-05118-w  0.083
2023 Colloca L, Nikayin S, Sanacora G. The Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents. Jama Psychiatry. PMID 37405764 DOI: 10.1001/jamapsychiatry.2023.1412  0.05
2022 Wilkinson ST, Sanacora G. At-home ketamine; still a lot to learn. Journal of Affective Disorders. 318: 150-151. PMID 36067887 DOI: 10.1016/j.jad.2022.08.090  0.019
Hide low-probability matches.